control (open histogram).

Spark Violet[™] 538 anti-human CD3

Catalog # / Size:		
Clone:	UCHT1	λ.
lsotype:	Mouse IgG1, к	
Reactivity:	Human, Other	
Preparation:	The antibody was purified by affinity chromatography and conjugated with Spark Violet™ 538 under optimal conditions.	Relative Cell Number
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)	0 103 104 105 Log Fluorescence Intensity
Workshop Number:	III 471	Human peripheral blood lymphocytes were stained with
Concentration:	Lot-specific	CD3 (clone UCHT1) Spark Violet™ 538 (filled histogram) or mouse IgG1, k Spark Violet™ 538 isotype

Applications:

Applications: Flow Cytometry

Recommended Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the Usage: suggested use of this reagent is 5 μ L per million cells in 100 μ L staining volume or 5 μ L per 100 μ L of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

> * Spark Violet[™] 538 has a maximum excitation of 396 nm and a maximum emission of 538 nm.

Additional reported applications (for the relevant formats) include: Application Notes: immunohistochemical staining of acetone-fixed frozen sections^{4,6,7} and formalin-fixed paraffin-embedded sections¹¹, immunoprecipitation¹, activation of T cells^{2,3,5}, and Western blotting⁹. The LEAF[™] purified antibody (Endotoxin < 0.1 EU/ μ g, Azide-Free, 0.2 μ m filtered) is recommended for functional assays (Cat. No. 300413, 300414, and 300432). For highly sensitive assays, we recommend Ultra-LEAF[™] purified antibody (Cat. No. 300437, 300438, 300465, 300466, 300473, 300474) with a lower endotoxin limit than standard LEAF[™] purified antibodies (Endotoxin < 0.01 EU/µg).

Application References:	 Salmeron A, et al. 1991. J. Immunol. 147:3047. (IP) Graves J, et al. 1991. J. Immunol. 146:2102. (Activ) Lafont V, et al. 2000. J. Biol. Chem. 275:19282. (Activ) Ryschich E, et al. 2003. Tissue Antigens 62:48. (IHC) Thompson AG, et al. 2004. J. Immunol. 173:1671. (Activ) Sakkas LI, et al. 1998. Clin. Diagn. Lab. Immun. 5:430. (IHC) Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC) Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed Van Dongen JJM, et al. 1988. Blood 71:603. (WB) Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Pollard, K. et al. 1987. J. Histochem. Cytochem. 35:1329. (IHC) Luckashenak N, et al. 2013. J. Immunol. 190:27. PubMed Laurent AJ, et al. 2014. PLoS One. 9:103683. PubMed Li J, et al. 2015. Cancer Res. 75:508. PubMed Stoeckius M, et al. 2017. Nat. Methods. 14:865-868. (PG)
	15. Stoeckius M, et al. 2017. Nat. Methods. 14:865-868. (PG)

Description:	CD3 ϵ is a 20 kD chain of the CD3/T-cell receptor (TCR) complex which is composed of two CD3 ϵ , one CD3 γ , one CD3 δ , one CD3 ζ (CD247), and a T- cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T cells, NKT cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal
	transduction, and T cell activation.

Antigen1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. SanReferences:Diego.

- 2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
- 3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.